Clinical Investigator FMV

Structuring Contracts and Planning Investigator Meetings

Clinical Investigator FMV


The benchmarks in this report are designed to help clinical managers determine how, what and when to pay clinical investigators. Findings help readers to leverage multiple sources to calculate accurate fair-market value, allocate principal investigator compensation, build comprehensive trial budgets and plan for pass-through costs. Teams can use the report’s insights to structure investigator contracts, keep quarterly budgets intact and build precise investigator meeting budgets.

  • Description
  • Additional information



Clinical Investigator FMV: Structuring Contracts and Planning Investigator Meetings

  • Publication Date: August 2014
  • Pages: 102
  • Chapters: 3
  • Metrics: 400+
  • Charts/Graphics: 50+
Report Features

Clinical trials are unique by nature. The payment structures that support these investigations also differ greatly from study to study. Although compensation plans may be adjusted to better suit an individual trial, companies have developed several best practices to streamline the payment process. Some of the insights contained in this study focus on the key considerations to building a payment plan for investigator compensation. It also provides ranges and averages of direct costs that investigators often pass through to sponsors.

Reason To Buy

To provide greater transparency for clinical trial payments, most companies have moved to systems that pay physicians based on the number and complexity of patient visits. The study details how companies use benchmarking to understand the key differences in fair-market value payments for different specialists. It also includes biopharmaceutical partners’ key lingo and clinical investigator activity definitions as well as metrics of companies’ annual compensation limits. Investigator meetings are opportunities for investigators to become engaged with pharmaceutical companies and their products. Many companies turn to vendors to plan, organize and even run their investigator meetings. To prepare, event planners should build itemized budgets by calculating the cost per attendee. As a result, the number of participants will largely influence meeting budgets. The benchmarking data in this study delves into the critical aspects necessary for holding focused and engaging investigator meetings. To guide companies through these recommendations, the study presents investigator meeting budgets by both trial phase and reimbursed items.

Target Audience

– Clinical teams
– Compliance teams
– Medical affairs teams
– Legal teams
– Regulatory affairs
– Association of Clinical Research Professionals

Chapter Example

Regulators worldwide are urging pharmaceutical companies to justify physician payments. This push includes all compensation for activities, including medical speeches, journal publications and clinical trial operations. Authorities are looking for greater transparency, and that starts with fair-market value (FMV) analysis. But life science companies have been left without concrete guidance on how to calculate FMV.

Rather than see this lack of guidance as a hurdle, some companies have decided to create a process that is tailored to their needs. More established organizations look to their own historic physician payments as a means to justify future payments, whereas smaller companies must rely on industry benchmarks to feed FMV calculations. Regardless of company size, however, polling the industry strengthens FMV justification.